Secondary amyloidosis in a patient with long duration crohn's disease treated with infliximab

BioDrugs

Volumn 24, Issue SUPPL. 1, 2010, Pages 15-17

  Fidalgo, Catarina ^a   Calado, Joaquim ^b   Cravo, Marilia ^a  

^a INSTITUTO PORTUGUÊS DE ONCOLOGIA DE LISBOA FRANCISCO GENTIL   (Portugal)

^b HOSPITAL CURRY CABRAL   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; PREDNISOLONE;

ADULT; AMYLOIDOSIS; ANAMNESIS; ARTICLE; BODY MASS; BRONCHOSCOPY; CASE REPORT; CLINICAL FEATURE; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CROHN DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE DURATION; DRUG DOSE INCREASE; GLOMERULOPATHY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LABORATORY TEST; LUNG LAVAGE; MALE; PHYSICAL EXAMINATION; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; TREATMENT RESPONSE; URINALYSIS; X RAY;

ADULT; AMYLOID; AMYLOIDOSIS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CROHN DISEASE; HUMANS; MALE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650483395     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/11586250-000000000-00000     Document Type: Article

References (12)

1. Stokes M, Foster K, Markowitz G, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant 2005; 20: 1400-6
2. Lizuka M, Konno S, Horie Y, et al. Infliximab as a treatment for systemic amyloidosis associated with Crohn's disease. Gut 2006; 55: 744-5
3. Lachmann H, Goodman H, Gilbertson J, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-71
4. Basturk T, Ozagari A, Osturk T, et al. Crohn's disease and secondary amyloidosis: Early complication? A case report and review of the literature. J Renal Care 2009; 35 (3): 147-50
5. Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biologic inflammatory markers in clinically active Crohn's disease with normal C-reactive protein serum level. Inflamm Bowel Dis 2007; 13 (9): 1100-5
6. Vermeire S, Van Assche G, Rutgeerts P. The role of mucosal healing in the treatment of Crohn's disease and ulcerative colitis. EurGastroenterol Rev 2007; 10-11
7. Tada S, Iida M, Yao T, et al. Intestinal pseudo-obstruction in patients with amyloidosis: Clinicopathologic differences between chemical types of amyloid protein. Gut 1993; 34: 1412-17
8. Boscá M, Pérez-Baylach C, Solis M, et al. Secondary amyloidosis in Crohn's disease: Treatment with tumour necrosis factor inhibitor. Gut 2006; 55 (2): 294-5
9. Dember L, Hawkins P, Hazenberg B, et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007; 356 (23): 2349-60
10. Sandborn W, Rutgeerts P, Enns R, et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab - a randomized trial. Ann Intern Med 2007; 146 (12): 829-39
11. Horie Y, Chiba M, Miura K, et al. Crohn's disease associated with amyloidosis successfully treated with an elemental diet. J Gastroenterol 1997; 32: 663-7
12. Lovat B, Madhoo S, Pepys M, et al. Long-term survival in systemic A amyloidosis complicating Crohn's disease. Gastroenterology 1997; 112: 1362-5